Immatics N.V. (IMTX)

Mixed fundamentals with elevated clinical risk: a clinical-stage TCR immunotherapy company with a fortress balance sheet (roughly half a billion euros pro-forma after the August 2026 raise, negligible lease-only debt, clean audit, no going-concern) offset by deep and widening losses (€196.4M net loss in FY2025), negative operating cash flow, declining lumpy collaboration revenue, and frequent dilutive equity raises. The recurring earnings run-rate is loss-making - the FY2022/FY2024 profit years were one-time collaboration artifacts. Near-term value hinges on the SUPRAME Phase 3 melanoma readout expected in 1H 2027; consensus analyst target of $17 implies meaningful upside and Perceptive Advisors recently added shares at $8.69. Speculative with a defined catalyst; not distressed.

The $150M underwritten offering (announced Aug 25, completed Aug 26) is a fresh bearish supply overhang the tape has only partly absorbed — shares sit ~9% above the $8.69 offer price — offset by Perceptive Advisors' 863K-share open-market buy at that same $8.69 anchor, a media-covered insider conviction leg the market rewarded; the sentiment delta is determinate but flat (+0.14 baseline vs +0.07 scoring), retail velocity is indeterminate, the legal screen is clean, and moderate red-flag caps apply (opportunistic dilution on a healthy balance sheet; conflicting bearish/bullish signals in the same actionable window).

IMTX is in a persistent multi-month downtrend: price 8.62 trades below SMA20 (9.10), SMA50 (9.21) and SMA200 (9.94), below EMA9 (8.83) and EMA21 (9.02), and slightly below today's VWAP (8.68). Momentum is negative: MACD -0.18/-0.12/-0.06 with the line still declining, RSI14 39.73, Williams %R -79.71 (mildly oversold, not extreme), and ADX 15.02 indicates no directional strength behind the drift. Volume is adequate (20-day avg $5.81M) but down-day skewed. This is a weak-bearish, bounce-only chart at best; no bullish setup scores 3 or higher. A pullback/oversold limit is explicitly countertrend (below SMA50 with MACD < 0, and below a declining SMA200 without a momentum reclaim), and no breakout stop qualifies with MACD negative, RSI sub-45 and ADX 15.